Log in

NASDAQ:MYL - Mylan Stock Price, Forecast & News

$14.91
-0.16 (-1.06 %)
(As of 04/1/2020 07:42 AM ET)
Today's Range
$14.84
Now: $14.91
$15.80
50-Day Range
$13.26
MA: $17.49
$22.62
52-Week Range
$12.75
Now: $14.91
$28.88
Volume7.36 million shs
Average Volume10.28 million shs
Market Capitalization$7.70 billion
P/E Ratio497.17
Dividend YieldN/A
Beta1.75
Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded-generic, brand-name, and over-the-counter (OTC) pharmaceutical products in North America, Europe, and internationally. It offers active pharmaceutical ingredients and finished dosage forms; and antiretroviral medicines to treat HIV/AIDS. The company also provides prescription products, such as EpiPen Auto-Injector; Perforomist Inhalation Solution; Dymista; Creon; and Influvac, as well as YUPELRI, an inhalation solution for the maintenance treatment of patients with chronic obstructive pulmonary diseases. In addition, it markets OTC products, including Cold-EEZE, MidNite, Vivarin, Brufen, CB12, and EndWarts. The company offers its products to therapeutic areas, such as cardiovascular, CNS and anesthesia, dermatology, diabetes and metabolism, gastroenterology, immunology, infectious disease, oncology, respiratory and allergy, and women's health. Its customers include retail pharmacies, wholesalers and distributors, payers, and insurers and governments, as well as institutions, such as hospitals. Mylan N.V. has collaboration and license agreements with Pfizer Inc.; Momenta Pharmaceuticals, Inc.; TB Alliance; Theravance Biopharma, Inc.; Biocon Ltd.; and Fujifilm Kyowa Kirin Biologics Co. Ltd. The company was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.
Read More
Mylan logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Current SymbolNASDAQ:MYL
CUSIP62853010
Phone724-514-1800

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$11.50 billion
Cash Flow$8.24 per share
Book Value$23.02 per share

Profitability

Net Income$16.80 million

Miscellaneous

Employees35,000
Market Cap$7.70 billion
Next Earnings Date5/5/2020 (Estimated)
OptionableOptionable

Receive MYL News and Ratings via Email

Sign-up to receive the latest news and ratings for MYL and its competitors with MarketBeat's FREE daily newsletter.


Mylan (NASDAQ:MYL) Frequently Asked Questions

How has Mylan's stock been impacted by COVID-19 (Coronavirus)?

Mylan's stock was trading at $14.47 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, MYL stock has increased by 3.0% and is now trading at $14.91. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Mylan?

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mylan in the last year. There are currently 6 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Mylan.

When is Mylan's next earnings date?

Mylan is scheduled to release its next quarterly earnings announcement on Tuesday, May 5th 2020. View our earnings forecast for Mylan.

How were Mylan's earnings last quarter?

Mylan NV (NASDAQ:MYL) announced its earnings results on Thursday, February, 27th. The company reported $1.40 earnings per share for the quarter, beating the consensus estimate of $1.28 by $0.12. The company had revenue of $3.19 billion for the quarter, compared to the consensus estimate of $3.22 billion. Mylan had a net margin of 0.15% and a return on equity of 19.35%. The company's revenue was up 3.7% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.30 EPS. View Mylan's earnings history.

What guidance has Mylan issued on next quarter's earnings?

Mylan updated its FY 2020 After-Hours earnings guidance on Thursday, February, 27th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $11.5-12.5 billion, compared to the consensus revenue estimate of $11.92 billion.

What price target have analysts set for MYL?

15 analysts have issued 1-year price objectives for Mylan's stock. Their forecasts range from $18.00 to $36.00. On average, they expect Mylan's share price to reach $25.89 in the next twelve months. This suggests a possible upside of 73.7% from the stock's current price. View analysts' price targets for Mylan.

What are Wall Street analysts saying about Mylan stock?

Here are some recent quotes from research analysts about Mylan stock:
  • 1. According to Zacks Investment Research, "Mylan received a significant boost, when the FDA approved its generic version of Advair Diskus — WixelaInhub — following a few setbacks. The biosimilars portfolio is also gaining traction with a few important approvals. However, Mylan’s generic business is experiencing a slowdown. The company proactively discontinued a number of products along with transferring some to other sites. These have led to a temporary disruption in the supply of certain products and reduced volumes in North America generic sales. The FDA approved rival Teva Pharmaceutical’s generic version of EpiPen and EpiPen Jr, which, in turn, will negatively impact sales further. Moreover, slower-than-expected uptake of generic Copaxone, even after reducing the price by more than 60%, adversely impacted sales in North America. Shares have underperformed the industry in the past six months." (4/30/2019)
  • 2. Cantor Fitzgerald analysts commented, ". We are lowering our 1Q19 EPS estimate for MYL to $0.70 from $0.88. The decrease in our estimate is based on comments the company made at a conference on 3/5/19. This does not affect our investment thesis, and we are thus maintaining our Neutral rating and 12-month PT of $41." (4/1/2019)

Has Mylan been receiving favorable news coverage?

News headlines about MYL stock have trended very negative on Wednesday, according to InfoTrie Sentiment Analysis. InfoTrie identifies negative and positive media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Mylan earned a media sentiment score of -3.0 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 4.0 out of 10, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the next few days. View the latest news aboutMylan.

Are investors shorting Mylan?

Mylan saw a increase in short interest during the month of March. As of March 13th, there was short interest totaling 21,509,300 shares, an increase of 6.5% from the February 27th total of 20,200,000 shares. Based on an average daily trading volume, of 9,380,800 shares, the short-interest ratio is currently 2.3 days. Approximately 4.2% of the company's shares are short sold. View Mylan's Current Options Chain.

Who are some of Mylan's key competitors?

What other stocks do shareholders of Mylan own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Mylan investors own include Gilead Sciences (GILD), Alibaba Group (BABA), Teva Pharmaceutical Industries (TEVA), Micron Technology (MU), NVIDIA (NVDA), Intel (INTC), Starbucks (SBUX), Allergan (AGN), Pfizer (PFE) and General Electric (GE).

Who are Mylan's key executives?

Mylan's management team includes the following people:
  • Ms. Heather Bresch, CEO & Exec. Director (Age 50)
  • Mr. Rajiv Malik, Pres & Exec. Director (Age 58)
  • Mr. Kenneth S. Parks, Chief Financial Officer (Age 56)
  • Mr. Anthony Mauro, Chief Commercial Officer (Age 46)
  • Mr. Daniel M. Gallagher Jr., Advisor (Age 46)

What is Mylan's stock symbol?

Mylan trades on the NASDAQ under the ticker symbol "MYL."

How do I buy shares of Mylan?

Shares of MYL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Mylan's stock price today?

One share of MYL stock can currently be purchased for approximately $14.91.

How big of a company is Mylan?

Mylan has a market capitalization of $7.70 billion and generates $11.50 billion in revenue each year. The company earns $16.80 million in net income (profit) each year or $4.42 on an earnings per share basis. Mylan employs 35,000 workers across the globe. View additional information about Mylan.

What is Mylan's official website?

The official website for Mylan is http://www.mylan.com/.

How can I contact Mylan?

Mylan's mailing address is 1000 MYLAN BOULEVARD, CANONSBURG PA, 15317. The company can be reached via phone at 724-514-1800 or via email at [email protected]


MarketBeat Community Rating for Mylan (NASDAQ MYL)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  749 (Vote Outperform)
Underperform Votes:  615 (Vote Underperform)
Total Votes:  1,364
MarketBeat's community ratings are surveys of what our community members think about Mylan and other stocks. Vote "Outperform" if you believe MYL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MYL will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 4/1/2020 by MarketBeat.com Staff

Featured Article: QQQ ETF

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel